#ValuePro

[poleznotut]

CyberPower Value Pro — надёжная защита для вашего оборудования ⚡🖥️

Представляем серию источников бесперебойного питания (ИБП) CyberPower Value Pro, разработанных специально для защиты офисных устройств от перебоев в электропитании. Эти ИБП формата Tower 🏢, линейно-интерактивного типа, эффективно защищают от скачков напряжения, вызванных внешними факторами, такими как грозы. ⛈️

🔧 Основные характеристики:

Модели с выходной мощностью: 700, 1000, 1200 и 1600 ВА. Диапазон входного напряжения: от 170 до 295 В. Частота: 50–60 Гц. На выходе: 230 В переменного тока. Съёмный сетевой кабель с разъёмом IEC C14. Модифицированная синусоида ⚙️, подходящая для большинства офисных устройств.

🔋 Особенности: Выходные разъёмы на выбор: IEC C13 или розетки Schuko. Защита от перепадов и бросков напряжения 🌩️. Время переключения на батарею — 10 миллисекунд. Встроенная система автоматического регулирования напряжения (AVR). Экономичная и экологичная технология GreenPower UPS™ 🌱. Многофункциональная ЖК-панель 📊 для отслеживания состояния системы. ПО PowerPanel® для мониторинга и управления.

ИБП CyberPower Value Pro оснащены заменяемыми свинцово-кислотными батареями, которые заряжаются за 8 часов. Благодаря технологии AVR, система защищает оборудование от низкого напряжения и перенапряжений, а встроенное ПО позволяет удобно управлять системой через веб-портал или мобильное приложение 📱.

Почему стоит выбрать CyberPower Value Pro?

Надёжность ✅ Компактность 🛠️ Стильный дизайн 💼 Официальная гарантия от АйДистрибьют, официального поставщика продукции CyberPower в России.

🔗 Купить ИБП CyberPower Value Pro можно на нашем сайте: https://idistribute.ru/news/ibp_cyberpower_value_pro/ 💻

[internetsites]

CyberPower Value Pro — надёжная защита для вашего оборудования ⚡🖥️

Представляем серию источников бесперебойного питания (ИБП) CyberPower Value Pro, разработанных специально для защиты офисных устройств от перебоев в электропитании. Эти ИБП формата Tower 🏢, линейно-интерактивного типа, эффективно защищают от скачков напряжения, вызванных внешними факторами, такими как грозы. ⛈️

🔧 Основные характеристики:

Модели с выходной мощностью: 700, 1000, 1200 и 1600 ВА. Диапазон входного напряжения: от 170 до 295 В. Частота: 50–60 Гц. На выходе: 230 В переменного тока. Съёмный сетевой кабель с разъёмом IEC C14. Модифицированная синусоида ⚙️, подходящая для большинства офисных устройств.

🔋 Особенности: Выходные разъёмы на выбор: IEC C13 или розетки Schuko. Защита от перепадов и бросков напряжения 🌩️. Время переключения на батарею — 10 миллисекунд. Встроенная система автоматического регулирования напряжения (AVR). Экономичная и экологичная технология GreenPower UPS™ 🌱. Многофункциональная ЖК-панель 📊 для отслеживания состояния системы. ПО PowerPanel® для мониторинга и управления.

ИБП CyberPower Value Pro оснащены заменяемыми свинцово-кислотными батареями, которые заряжаются за 8 часов. Благодаря технологии AVR, система защищает оборудование от низкого напряжения и перенапряжений, а встроенное ПО позволяет удобно управлять системой через веб-портал или мобильное приложение 📱.

Почему стоит выбрать CyberPower Value Pro?

Надёжность ✅ Компактность 🛠️ Стильный дизайн 💼 Официальная гарантия от АйДистрибьют, официального поставщика продукции CyberPower в России.

🔗 Купить ИБП CyberPower Value Pro можно на нашем сайте: https://idistribute.ru/news/ibp_cyberpower_value_pro/ 💻

[petnews2day]

Hardware News and Tech Reviews Since 1997

New Post has been published on https://petnews2day.com/pet-news/small-pet-news/hardware-news-and-tech-reviews-since-1997/

Hardware News and Tech Reviews Since 1997

In today’s review, we are taking a look at the ValuePro VP1600ELCD, a popular low-cost UPS from CyberPower, the renowned US-based power systems manufacturer. As the name suggests, it…

20 by E. Fylladitakis on 10/28/2022

[ireneestep5]

Jameco Valuepro IG406D2341 Key Lock Switch Single Pole Single Throw Round Terminal Key #2341 All Keyed Alike

[khushiprakash]

Jameco Valuepro 830-Point Solderless Breadboard, 6.5" x 2.125", 0.1" spread, Ideal for Prototyping and Classroom Projects - WBU-202-R https://news99india.in/jameco-valuepro-830-point-solderless-breadboard-6-5-x-2-125-0-1-spread-ideal-for-prototyping-and-classroom-projects-wbu-202-r/?feed_id=51336&_unique_id=5fba0e17674f3

[eqtmonline03-blog]

Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying

Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels. Gains were largely seen in the healthcare sector and power sector.

Both, the Sensex and Nifty, ended their day at record closing highs. At the closing bell, the BSE Sensex stood higher by 7 points (up 0.02%) and the NSE Nifty closed higher by 19 points (up 0.17%). The BSE Mid Cap index ended the day up by 0.5%, while the BSE Small Cap index ended the day up by 0.3%.

Asian stock markets finished on a positive note as of the most recent closing prices. The Hang Seng stood up by 0.56% and the Nikkei was trading up by 0.09%. The Shanghai Composite stood higher by 1.29%.

European markets were trading on a mixed note. The FTSE 100 was down by 0.23%. The DAX was up by 0.63% while the CAC 40 was up by 0.75%.

The rupee was trading at 69.85 to the US$ at the time of writing.

In the news from pharma space, Lupin share price was in focus today as the company said it has received final approval from the United States Food and Drug Administration (USFDA) to market Hydrocortisone Butyrate lotion.

Hydrocortisone Butyrate Lotion is the generic version of PreCision’s Locoid Lotion, 0.1%. It is a corticosteroid indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.

As per the data, the lotion had annual sales of approximately US$ 13.8 million in the US.

Owing to the above news, Lupin share price witnessed buying interest and ended the day up by 2.2% on the BSE.

Speaking of drug approvals, Indian pharma companies catering to the US markets are breathing a sigh of relief. After being adversely affected by import bans and the suspension of new drug approvals from manufacturing facilities in the past three years, there has been a sharp pick-up in new drug approvals in FY17.

Generic Drug Approvals Hit the Roof

Even the total filings of abbreviated new drug applications (ANDAs) for generic drugs rose to 1,292 in FY17 from 852 in FY16. While faster approvals expedite the commercialization of product pipelines of domestic pharma companies spurring growth, at the same time, however, it has raised the intensity of competition resulting in pricing pressures. The price erosion has been further compounded by a consolidation among US distributors and the decline in the number of products going off-patent over the past few years.

In other words, acceleration in generic drug approvals is like a double-edged sword. The growth boost can be quickly offset by the ensuing pricing pressures. Pharma companies that invest in creating a pipeline of complex generics or building competencies in alternative dosage forms are better equipped to tackle the changing dynamics in the US generics market.

Therefore, despite a lot of pessimism surrounding pharma stocks on regulatory uncertainty, we have stocks in open positions in our premium safe stocks recommendation service StockSelect and have also remained bullish on pharma stocks in our long term service, ValuePro.

Moving on, airline stocks were also witnessing buying interest today. Gains were seen as official data showed that domestic passenger traffic grew 21% in July on a year-on-year (YoY) basis.

As per the data released by the Directorate General of Civil Aviation (DGCA), domestic airlines carried 11.6 million passengers in July this year.

The country’s largest domestic airline, IndiGo increased its monthly passenger count by 31.7% YoY to 4.86 million. Jet Airways reported 0.5% YoY growth with 1.74 million tourists booking its flights. National carrier Air India recorded a 10.7% YoY growth in air traffic, carrying 1.43 million passengers, while SpiceJet carried 1.42 million passengers in July, up 5% YoY.

For GoAir, domestic passenger traffic grew by 38.4% YoY to 1.02 million and the same for AirAsia and Vistara was 0.55 million and 0.45 million passengers, respectively, up by 62% and 29% YoY.

Note that India’s aviation industry is on a high-growth trajectory. India’s domestic air traffic has seen a prolific growth of 20–25% during 2015 and 2016. And in 2017, it tapered to 17.4%. However, for the first time, domestic air traffic crossed an important landmark of 100 million passengers in a calendar year.

Air travel has recorded double-digit growth for 40 consecutive months, thanks to low fares, the addition of new flights/destinations, and overall growth in the economy.

What’s foreseeable for India’s aviation traffic in 2018 is some pressure on the back of the consistent rise in crude oil prices.

Oil prices are closely monitored by the Indian air carriers, as aviation turbine fuel is their single largest input cost. A sharp rise in the cost of fuel puts pressure on margins, and consequently an increase in air fares.

Although air travel is becoming the new normal, investors need to understand the industry dynamics before buying up aviation stocks.

To know what’s moving the Indian stock markets today, check out the most recent share market updates here.

Now you can also listen to our stock market podcast. In the latest edition of our podcast, we have talked about the falling rupee, trade deficit, and the how Turkish crisis can affect your portfolio of stocks. Just visit SoundCloud, iTunes or Stitcher and access our free weekly podcast. Happy listening!

This article was originally published in English at www.equitymaster.com

Read the complete Indian stock market update. For the terms of use, go here.

[khushiprakash]

Jameco Valuepro GB165LB Push Button Rocker Slide Toggle and Slide Switch Grab Bag https://news99india.in/jameco-valuepro-gb165lb-push-button-rocker-slide-toggle-and-slide-switch-grab-bag/?feed_id=46832&_unique_id=5fae1e7ac131a

[eqtmonline03-blog]

Sensex, Nifty Close at Record Highs; Banking Stocks Witness Buying

Sensex, Nifty Close at Record Highs; Banking Stocks Witness Buying

Indian share markets continued their momentum during closing hours of trade and ended the day on a positive note. Gains were largely seen in the energy sector, telecom sector and banking sector.

Both, the Senses and Nifty, ended their day at record closing highs. At the closing bell, the BSE Sensex stood higher by 222 points (up 0.6%) and the NSE Nifty closed higher by 61 points (up 0.5%). The BSE Mid Cap index ended the day up by 0.2%, while the BSE Small Cap index ended the day flat.

Asian stock markets finished on a mixed note as of the most recent closing prices. The Hang Seng stood up by 0.39% and the Nikkei was trading down by 0.08%. The Shanghai Composite stood lower by 1.25%.

European markets were trading on a positive note. The FTSE 100 was up by 0.84%. The DAX, was up by 0.32% while the CAC 40 was up by 0.10%.

The rupee was trading at 68.62 to the US$ at the time of writing.

Speaking of rising markets, In June 2016, when Sensex was trading at around 27,000 mark, Tanushree shared with her subscribers a report on why Sensex could go up to 40,000…. And the four safe stocks that one could count on to create permanent wealth.

Sensex is close to that mark now. But the way Tanushree sees things now, the Sensex is on its way to hit 100,000 mark by the next decade.

That said, she believes it’s not going to be a continuous joy ride. In fact, a majority of these gains will be led by stocks outside of the Sensex.

How can regular investors make sure NOT to miss this ride?

So Tanushree created a blueprint of stocks that will create permanent wealth for her subscribers.

If there is one blueprint all investors — especially if you are new to the markets — need for long term success, it is this. Today is the last day the blueprint will be available. See the video here and get 3 stocks you should invest in straight away.

Remember — this closes at midnight tonight. Click here now.

In the news from pharmaceuticals sector, Lupin share price was in focus today as the company reported a 44% year-on-year (YoY) decline in net profit at Rs 2,028 million for the quarter ended June.

Total income during the quarter grew 3.6% YoY to Rs 40 billion.

The subdued performance was primarily seen on the account of lower sales in the US and Japan. Sales in North America, the company’s largest market, fell 26%.

Also, a rise in tax rate to 47% from 21% in the corresponding quarter also hit earnings.

At the closing bell, Lupin share price stood down by 4.5% on the BSE.

Speaking of pharma sector, note that the BSE Healthcare Index has been on a roller coaster ride in the past few years. The period from 2012 to 2015 saw the index go up more than three times.

And since then it has been a painful ride downwards, as can be seen from the chart below:

The Roller Coaster Ride of the BSE Healthcare Index

As we wrote in one of our editions of The 5 Minute WrapUp…

Pre-2015, pharma companies enjoyed a fairytale ride in the US market. Low labor costs, good chemistry skills, along with efficiency, ensured Indian companies could copy innovator drugs to make generic drugs at a fast pace.

The generic business had lucrative margins for all major pharma players. But the party did not last long. In the quest to supply drugs quickly, they compromised on quality at their manufacturing facilities.

No wonder, the US regulatory authority (USFDA) took strict action. Sun Pharma received a warning letter for its Halol manufacturing facility in 2015. It was like a bolt out of the blue. Since then, the downward spiral began and has continued till date.

We believe that pharma companies that invest in creating a pipeline of complex generics or building competencies in alternative dosage forms are better equipped to tackle the changing dynamics in the US generics market as well as in the overall industry.

Therefore, despite a lot of pessimism surrounding pharma stocks on regulatory uncertainty, we have stocks in open positions in StockSelect and have remained bullish on pharma stocks in our long term service, ValuePro.

In news from the , Mphasis share price was also in focus today. Shares of the company witnessed selling pressure as the company’s board approved a proposal to buy back shares worth of up to Rs 9.8 billion.

It also said that promoters of the company have intentions to participate in the buyback and the buyback of shares will be done at a maximum price of Rs 1,350 per share.

Mphasis share price closed the day down by 3.5% on the BSE.

Speaking of buybacks, the number of buyback offers in 2017–18 were at an all-time high. Never, in the last two decades, Indian markets saw fifty-nine companies announcing buyback plans.

As per Rahul Shah, co-head of Research, investors should not assume buybacks are always good. Here’s an excerpt of what he wrote in one of the editions of The 5 Minute Wrapup:

The reason behind the buyback must be investigated. At the end of the day, an increase in earnings should be more a function of the inherent robustness of the business, as that’s what will help it continue to grow at a healthy pace.

At Equitymaster, we believe, as a shareholder in cash rich companies, you should not only be wary of expensive buybacks. But if possible use it to your advantage to rake in some cash.

It’s a matter of time before you get to use the cash for buying stocks, you’ve always wanted to, at attractive bargains.

This article was originally published in English at www.equitymaster.com

Read the complete Indian stock market update. For the terms of use, go here.

[eqtmonline03-blog]

Indian Indices Trade Marginally Higher; Banking and Telecom Stocks Witness Buying

Share markets in India are presently trading marginally higher. Sectoral indices are trading on a positive note with stocks in the banking sector, metal sector and telecom sector witnessing maximum buying interest.

The BSE Sensex is trading up by 157 points (up 0.4%), while the NSE Nifty is trading up by 34 points (up 0.3%). The BSE Mid Cap index is trading up by 0.4%, while the BSE Small Cap index is trading up by 0.6%.

The rupee is trading at 68.68 to the US$.

In the news from pharma space, Alembic Pharmaceuticals share price is in focus today. This comes as the company has received tentative approval from the US Food and Drug Administration (USFDA) for Bimatoprost Ophthalmic Solution, used to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness.

As per the company filing, the tentatively approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug product (RLQ), LATISSE ophthalmic solution, 0.03% of Allergan.

The drug had an estimated market size of US$ 63 million for 12 months ending December 2017.

At the time of writing, Alembic Pharmaceuticals share price was trading up by 1.6% on the BSE.

Indian pharma companies catering to the US markets are breathing a sigh of relief. After being adversely affected by import bans and the suspension of new drug approvals from manufacturing facilities in the past three years, there has been a sharp pick-up in new drug approvals in FY17.

With an aim to lower the overall healthcare costs in the country, the US Food and Drug Administration (FDA) approved a record 763 generic drugs for the financial year ending 30th September. As per Mint Analysis, Indian pharma companies received 295 approvals accounting for 40% of the overall approvals during the year.

Generic Drug Approvals Hit the Roof

Even the total filings of abbreviated new drug applications (ANDAs) for generic drugs rose to 1,292 in FY17 from 852 in FY16. While faster approvals expedite the commercialization of product pipelines of domestic pharma companies spurring growth, at the same time, however, it has raised the intensity of competition resulting in pricing pressures. The price erosion has been further compounded by a consolidation among US distributors and the decline in the number of products going off-patent over the past few years.

In other words, acceleration in generic drug approvals is like a double-edged sword. The growth boost can be quickly offset by the ensuing pricing pressures. Pharma companies that invest in creating a pipeline of complex generics or building competencies in alternative dosage forms are better equipped to tackle the changing dynamics in the US generics market.

Therefore, despite a lot of pessimism surrounding pharma stocks on regulatory uncertainty, we have stocks in open positions in StockSelect and have remained bullish on pharma stocks in our long term service, ValuePro.

In the news from initial public offering (IPO) space, HDFC Asset Management Company (AMC) made a stellar debut on the bourses today. The scrip of the company got listed at Rs 1,739 on BSE, around 58% premium to its issue price of Rs 1,100.

HDFC AMC's Rs 28-billion initial public offer was open during July 25-27. Price band for the offer was fixed at Rs 1,095-1,100 per share.

The IPO was of 25,457,555 shares, including anchor portion of 6,653,265 shares. HDFC AMC operates as a joint venture between Housing Development Finance Corporation (HDFC) and Standard Life Investments.

To know more about the company, you can read our IPO analysis of HDFC Asset Management Company (AMC) Ltd(requires subscription).

At the time of writing, HDFC AMC share price was trading at Rs 1,804, up by 64% over its issue size.

This article was originally published in English at www.equitymaster.com

Read the complete Indian stock market update. For the terms of use, go here.

[eqtmonline03-blog]

Sensex Opens Day Flat; Pharma Stocks Top Gainers

Asian share markets are mixed today as Chinese and Hong Kong shares fall. The Nikkei 225 is up 0.4% while the Hang Seng is down 0.6%. The Shanghai Composite is trading down by 0.8%.

Back home, India share markets opened the day on a flat note with a positive bias. The BSE Sensex is higher by 52 points while the NSE Nifty is trading up by 28 points. The BSE Mid Cap index and BSE Small Cap index both opened the day up by 0.2% & 0.3% respectively.

Sectoral indices have opened the day on a mixed note with pharma stocks and stocks in the consumer durables sector witnessing maximum buying interest. The rupee is trading at 67.35 to the US$.

In news from stocks in the pharma sector. Sun Pharma share price is among the most active stocks today as the company' received an establishment inspection report (EIR) from the US Food and Drug Administration (USFDA).

The company received the establishment inspection report (EIR) for its for its critical Halol facility in Gujarat indicating a closure of inspection.

As per USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspection findings.

Sun Pharma's Halol plant was issued form 483 with 23 observations way back in 2014. Further re-inspections also ended with warning letters and a form 483. Finally, after the most recent inspection of the company's Halol plant from 12-23 February 2018 the US regulator awarded a 'voluntary action initiated' (VAI) last week, and the EIR followed subsequently.

Sun Pharma share price opened the day up by 3%.

Indian pharma companies catering to the US markets are breathing a sigh of relief. After being adversely affected by import bans and the suspension of new drug approvals from manufacturing facilities in the past three years, there has been a sharp pick-up in new drug approvals in FY17. With an aim to lower the overall healthcare costs in the country, the US Food and Drug Administration (FDA) approved a record 763 generic drugs for the financial year ending 30th September. As per Mint Analysis, Indian pharma companies received 295 approvals accounting for 40% of the overall approvals during the year.

Generic Drug Approvals Hit The Roof

Even the total filings of abbreviated new drug applications (ANDAs) for generic drugs rose to 1,292 in FY17 from 852 in the previous year. While, faster approvals expedite the commercialisation of product pipelines of domestic pharma companies spurring growth. At the same time however, it has raised the intensity of competition resulting in pricing pressures. The price erosion has been further compounded by a consolidation among US distributors and the decline in the number of products going off-patent over the past few years.

In other words, acceleration in generic drug approvals is like a double-edged sword. The growth boost can be quickly offset by the ensuing pricing pressures. Pharma companies that invest in creating a pipeline of complex generics or building competencies in alternative dosage forms are better equipped to tackle the changing dynamics in the US generics market.

Therefore, despite a lot of pessimism surrounding pharma stocks on regulatory uncertainty, we have stocks in open positions in StockSelect and have remained bullish on pharma stocks in our long term service, ValuePro.

Moving on to news from stocks in the auto sector. Bharat Forge share price is in focus today after the company along with its wholly owned subsidiary Bharat Forge International UK purchased a stake in UK-based Tevva Motors.

Notably, Teeva provides electric powertrain solutions for trucks and buses, and currently provides EV solutions to the 7.5 -14 tonne weight commercial vehicle category. This is soon to be extended for the development of new commercial vehicles.

Bharat Forge along with its subsidiary picked up a stake of 35.26% in Teeva Motors for around £10 million. This is Bharat Forge's third major initiative in the EV space, and comes shortly after the start of the Engineering and Development Centre at MIRA, UK and the investment in Tork Motorcycles India (an electric drivetrain company, mainly focused on electric two wheelers).

Bharat Forge share price opened the day up by 1.8%.

This article was originally published in English at www.equitymaster.com

Read the complete Indian stock market update. For the terms of use, go here.